High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy (Q47631771)

4 February 2018

title

High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy (English)

1 reference

4 February 2018

1 reference

3

1 reference

4 February 2018

Rafael Fonseca

5

1 reference

4 February 2018

Mark R Litzow

12

Litzow MR

1 reference

4 February 2018

Morie A Gertz

13

Gertz MA

1 reference

4 February 2018

John A. Lust

9

Lust JA

1 reference

4 February 2018

Martha Q Lacy

2

Lacy MQ

1 reference

4 February 2018

author name string

Kumar S

1

1 reference

4 February 2018

Rajkumar SV

4

1 reference

4 February 2018

Geyer S

6

1 reference

4 February 2018

Allmer C

7

1 reference

4 February 2018

Witzig TE

8

1 reference

4 February 2018

Greipp PR

10

1 reference

4 February 2018

Kyle RA

11

1 reference

4 February 2018

language of work or name

English

0 references

publication date

1 July 2004

1 reference

4 February 2018

Bone Marrow Transplantation

published in

1 reference

4 February 2018

volume

34

1 reference

4 February 2018

issue

2

1 reference

4 February 2018

page(s)

161-167

1 reference

4 February 2018

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704545

exact match

0 references

cites work

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

Review of 1027 patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an 'operational cure'?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

Treatment approaches for relapsing and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

Treatment of primary resistant or relapsed multiple myeloma with high-dose chemoradiotherapy, hematopoietic stem cell rescue, and granulocyte-macrophage colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

7 January 2021

Long-term survival in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

7 January 2021

Combination chemotherapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

7 January 2021

Autologous stem cell transplantation for relapsed and primary refractory myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

7 January 2021

High-dose intravenous melphalan for plasma-cell leukaemia and myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

7 January 2021

High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

7 January 2021

Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

7 January 2021

Effect of complete response on outcome following autologous stem cell transplantation for myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704545

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704545

1 reference

4 February 2018

PubMed ID

15133489

1 reference

4 February 2018